Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?

The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.

Related Keywords

,Vertex Pharmaceuticals ,Drug Administration ,Bluebird Bio ,Motley Fool Stock Advisor ,Stock Advisor ,Crispr Therapeutics ,Red Blood Cells ,Sickle Cell Disease ,Fetal Hemoglobin ,Clinical Trial ,Food And Drug Administration ,